In a recent article in Ophthalmology, researchers shared the results of a study evaluating whether use of anti-vascular endothelial growth factor (VEGF) therapies to treat “wet” AMD increased the risk of acute myocardial infarction (AMI) or stroke for patients receiving such therapies.

The treatment group consisted of patients with a first diagnosis of wet AMD in 2006, when the widespread use of anti-VEGF therapies began. Patients newly diagnosed with wet AMD in 2000 (when anti-VEGF therapies were not available), or dry AMD in 2000 or 2006 were control groups.

The study concluded that introducing anti-VEGF therapies in 2006 to treat “wet” AMD did not increase the risk of AMI or stroke.

Click here ^[1] to read the full abstract.